Xanthine-oxidase inhibitors and statins in chronic heart failure: Effects on vascular and functional parameters

Simple item page
dc.contributor.authorGreig, Douglas
dc.contributor.authorAlcaino, Hernan
dc.contributor.authorCastro, Pablo F.
dc.contributor.authorGarcia, Lorena
dc.contributor.authorVerdejo, Hugo E.
dc.contributor.authorNavarro, Mario
dc.contributor.authorLopez, Rafael
dc.contributor.authorMellado, Rosemarie
dc.contributor.authorTapia, Fabiola
dc.contributor.authorGabrielli, Luigi A.
dc.contributor.authorNogerol, Camilo
dc.contributor.authorChiong, Mario
dc.contributor.authorGodoy, Ivan
dc.contributor.authorLavandero, Sergio
dc.date.accessioned2024-01-10T13:44:15Z
dc.date.available2024-01-10T13:44:15Z
dc.date.issued2011
dc.description.abstractBACKGROUND: Increased oxidative stress in heart failure (HF) leads to inflammation and endothelial dysfunction (ED). Both statins and allopurinol have known anti-oxidant properties, but their utility in HF has not been fully assessed.
dc.description.abstractMETHODS: This investigation was a prospective, double-blind, double-dummy study, performed between March 2007 and June 2009. Seventy-four HF patients, with New York Heart Association (NYHA) Class II or III status and left ventricular ejection fraction (LVEF) <40%, were included. Patients received placebo during 4 weeks and were then randomized to receive 4 weeks of either atorvastatin 20 mg/day plus placebo (ATV+PLA group) or atorvastatin 20 mg/day orally plus allopurinol 300 mg/day orally (ATV +ALLO group). Malondialdehyde (MDA), extracellular superoxide dismutase (ecSOD) activity and uric acid (UA) levels, among others, were determined at baseline and after 4 weeks of treatment. ED was assessed by flow-dependent endothelial-mediated vasodilation (FDD), and functional capacity by 6-minute walk test (6MWT).
dc.description.abstractRESULTS: Thirty-two patients were randomized to ATV+PLA and 38 to ATV+ALLO. Mean age was 59 +/- 2 years, 82% were male, and 22% had an ischemic etiology. Hypertension was present in 60% and diabetes in 15% of those studied. No significant differences were observed between baseline measurements and after placebo. After 4 weeks of treatment, both groups showed a significant decrease on MDA (0.9 +/- 0.1 to 0.8 +/- 0.1 and 1.0 +/- 0.5 to 0.9 +/- 0.1 mu mol/liter, p = 0.88), UA (7.4 +/- 0.4 to 6.8 +/- 0.3 and 7.2 +/- 0.4 to 5.0 +/- 0.3 mg/dl, p <0.01) and FDD (3.9 +/- 0.2% to 5.6 +/- 0.4% and 4.6 +/- 0.3% to 7.1 +/- 0.5%, p = 0.07) with increased ecSOD activity (109 +/- 11 to 173 +/- 13 and 98 +/- 10 to 202 +/- 16. U/ml/min, p = 0.41) and improved 6MWT (447 +/- 18 to 487 +/- 19 and 438 +/- 17 to 481 +/- 21 m, p = 0.83), with all values for ATV +PLA and ATV+ALLO, respectively; p-values are for comparison between groups after treatment.
dc.description.abstractCONCLUSION: Short-term ATV treatment in heart failure (HF) patients reduces oxidative stress and improves FDD and functional capacity. These beneficial effects are not strenghthened by the addition of alopurinol. J Heart Lung Transplant 2011;30:408-13 (C) 2011 International Society of Heart and Lung Transplantation. All rights reserved.
dc.description.funderCONICYT
dc.description.funderFONDECYT
dc.description.funderFONDAP
dc.fechaingreso.objetodigital25-03-2024
dc.format.extent6 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.healun.2010.10.003
dc.identifier.issn1053-2498
dc.identifier.pubmedidMEDLINE:21145258
dc.identifier.urihttps://doi.org/10.1016/j.healun.2010.10.003
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78874
dc.identifier.wosidWOS:000288924200007
dc.information.autorucMedicina;Castro P;S/I;100212
dc.information.autorucMedicina;Gabrielli LA ;S/I;11086
dc.information.autorucMedicina;Godoy I;S/I;70048
dc.information.autorucMedicina;Greig D;S/I;15418
dc.information.autorucQuímica;Mellado R ;S/I;109357
dc.information.autorucMedicina;Verdejo H ;S/I;1001175
dc.issue.numero4
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final413
dc.pagina.inicio408
dc.publisherELSEVIER SCIENCE INC
dc.revistaJOURNAL OF HEART AND LUNG TRANSPLANTATION
dc.rightsacceso restringido
dc.subjectallopurinol
dc.subjectstatins
dc.subjectheart failure
dc.subjectendothelial dysfunction
dc.subjectoxidative stress
dc.subjectOXIDATIVE STRESS
dc.subjectENDOTHELIAL DYSFUNCTION
dc.subjectURIC-ACID
dc.subjectCHRONOTROPIC RESPONSE
dc.subjectSUPEROXIDE DISMUTASE
dc.subjectALLOPURINOL
dc.subjectEXERCISE
dc.subjectATORVASTATIN
dc.subjectINFLAMMATION
dc.subjectRISK
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleXanthine-oxidase inhibitors and statins in chronic heart failure: Effects on vascular and functional parameters
dc.typeartículo
dc.volumen30
sipa.codpersvinculados100212
sipa.codpersvinculados11086
sipa.codpersvinculados70048
sipa.codpersvinculados15418
sipa.codpersvinculados109357
sipa.codpersvinculados1001175
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-03-25. Xanthine-oxidase inhibitors and statins in chronic heart failure - Effects on vascular and functional parameters.pdf
Size:
3.7 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas